CN112521501A - Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 - Google Patents

Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 Download PDF

Info

Publication number
CN112521501A
CN112521501A CN201910882351.2A CN201910882351A CN112521501A CN 112521501 A CN112521501 A CN 112521501A CN 201910882351 A CN201910882351 A CN 201910882351A CN 112521501 A CN112521501 A CN 112521501A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
ser
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910882351.2A
Other languages
English (en)
Chinese (zh)
Inventor
章华
汪笑峰
药晨江
张�成
景书谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongyun Huaning Hangzhou Biomedical Co ltd
Original Assignee
Hongyun Huaning Hangzhou Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongyun Huaning Hangzhou Biomedical Co ltd filed Critical Hongyun Huaning Hangzhou Biomedical Co ltd
Priority to CN201910882351.2A priority Critical patent/CN112521501A/zh
Priority to CN202310832321.7A priority patent/CN116942811A/zh
Priority to CN202510478075.9A priority patent/CN120289653A/zh
Priority to KR1020227012130A priority patent/KR20220063221A/ko
Priority to EP20866016.7A priority patent/EP4063385A4/en
Priority to JP2022517452A priority patent/JP2022549172A/ja
Priority to CA3154756A priority patent/CA3154756A1/en
Priority to PCT/CN2020/115483 priority patent/WO2021052349A1/zh
Priority to CN202080065099.7A priority patent/CN114641495B/zh
Priority to AU2020350715A priority patent/AU2020350715B2/en
Priority to MX2022003251A priority patent/MX2022003251A/es
Priority to US17/761,128 priority patent/US20220411520A1/en
Priority to TW114122821A priority patent/TW202613177A/zh
Priority to TW109132123A priority patent/TWI889705B/zh
Publication of CN112521501A publication Critical patent/CN112521501A/zh
Priority to JP2025112231A priority patent/JP2025165930A/ja
Priority to CL2025002476A priority patent/CL2025002476A1/es
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201910882351.2A 2019-09-18 2019-09-18 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 Pending CN112521501A (zh)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN201910882351.2A CN112521501A (zh) 2019-09-18 2019-09-18 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
PCT/CN2020/115483 WO2021052349A1 (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
MX2022003251A MX2022003251A (es) 2019-09-18 2020-09-16 Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos.
KR1020227012130A KR20220063221A (ko) 2019-09-18 2020-09-16 Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
EP20866016.7A EP4063385A4 (en) 2019-09-18 2020-09-16 GIPR ANTIBODIES AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1 AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
JP2022517452A JP2022549172A (ja) 2019-09-18 2020-09-16 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途
CA3154756A CA3154756A1 (en) 2019-09-18 2020-09-16 Gipr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
CN202310832321.7A CN116942811A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202080065099.7A CN114641495B (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
AU2020350715A AU2020350715B2 (en) 2019-09-18 2020-09-16 GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
CN202510478075.9A CN120289653A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
US17/761,128 US20220411520A1 (en) 2019-09-18 2020-09-16 Gipr antibody and fusion protein between same and glp-1, and pharmaceutical composition and application thereof
TW114122821A TW202613177A (zh) 2019-09-18 2020-09-17 Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
TW109132123A TWI889705B (zh) 2019-09-18 2020-09-17 Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
JP2025112231A JP2025165930A (ja) 2019-09-18 2025-07-02 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途
CL2025002476A CL2025002476A1 (es) 2019-09-18 2025-08-18 Anticuerpo contra gipr y su proteína de fusión con glp-1, su composición farmacéutica y aplicación

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910882351.2A CN112521501A (zh) 2019-09-18 2019-09-18 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Publications (1)

Publication Number Publication Date
CN112521501A true CN112521501A (zh) 2021-03-19

Family

ID=74883118

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201910882351.2A Pending CN112521501A (zh) 2019-09-18 2019-09-18 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202310832321.7A Pending CN116942811A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202510478075.9A Pending CN120289653A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202080065099.7A Active CN114641495B (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310832321.7A Pending CN116942811A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202510478075.9A Pending CN120289653A (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN202080065099.7A Active CN114641495B (zh) 2019-09-18 2020-09-16 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Country Status (10)

Country Link
US (1) US20220411520A1 (cg-RX-API-DMAC7.html)
EP (1) EP4063385A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022549172A (cg-RX-API-DMAC7.html)
KR (1) KR20220063221A (cg-RX-API-DMAC7.html)
CN (4) CN112521501A (cg-RX-API-DMAC7.html)
AU (1) AU2020350715B2 (cg-RX-API-DMAC7.html)
CA (1) CA3154756A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022003251A (cg-RX-API-DMAC7.html)
TW (2) TWI889705B (cg-RX-API-DMAC7.html)
WO (1) WO2021052349A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022259097A1 (en) * 2021-06-09 2022-12-15 Dragonstone Holding (Hong Kong) Limited Therapeutics and methods for treating or ameliorating metabolic disorders
WO2024051802A1 (zh) * 2022-09-08 2024-03-14 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白,以及其药物组合物和应用
WO2024094076A1 (zh) * 2022-11-02 2024-05-10 苏州康宁杰瑞生物科技有限公司 一种gipr结合蛋白及其应用
WO2025092705A1 (zh) * 2023-10-31 2025-05-08 山东博安生物技术股份有限公司 Gipr阻断型抗体及其抗体偶联物
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁(杭州)生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用
WO2026056998A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 Gipr结合分子及医药用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260139314A1 (en) * 2022-10-12 2026-05-21 Seoul National University Hospital Composition and method for predicting sulfonylurea dependency using gipr marker
TW202611076A (zh) * 2024-05-15 2026-03-16 大陸商信立泰(成都)生物技術有限公司 一種抗gipr抗體或其抗原結合片段及用途
WO2025252023A1 (en) * 2024-06-03 2025-12-11 Fortvita Biologics Inc. Modulators for gipr, glp1r and/or gcgr and uses thereof
WO2026093993A1 (en) * 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080767A (zh) * 2011-12-12 2014-10-01 瑞塞普托斯公司 新的glp-1受体调节剂
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US20180311372A1 (en) * 2017-01-17 2018-11-01 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CA3062194A1 (en) * 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
CN117126279A (zh) * 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080767A (zh) * 2011-12-12 2014-10-01 瑞塞普托斯公司 新的glp-1受体调节剂
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US20180311372A1 (en) * 2017-01-17 2018-11-01 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022259097A1 (en) * 2021-06-09 2022-12-15 Dragonstone Holding (Hong Kong) Limited Therapeutics and methods for treating or ameliorating metabolic disorders
WO2024051802A1 (zh) * 2022-09-08 2024-03-14 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白,以及其药物组合物和应用
WO2024094076A1 (zh) * 2022-11-02 2024-05-10 苏州康宁杰瑞生物科技有限公司 一种gipr结合蛋白及其应用
WO2025092705A1 (zh) * 2023-10-31 2025-05-08 山东博安生物技术股份有限公司 Gipr阻断型抗体及其抗体偶联物
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁(杭州)生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用
WO2026056998A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 Gipr结合分子及医药用途

Also Published As

Publication number Publication date
EP4063385A1 (en) 2022-09-28
CN114641495B (zh) 2025-05-02
EP4063385A4 (en) 2023-09-27
WO2021052349A1 (zh) 2021-03-25
TW202116803A (zh) 2021-05-01
AU2020350715B2 (en) 2026-08-13
TW202613177A (zh) 2026-04-01
JP2025165930A (ja) 2025-11-05
US20220411520A1 (en) 2022-12-29
AU2020350715A1 (en) 2022-04-14
MX2022003251A (es) 2022-04-27
KR20220063221A (ko) 2022-05-17
JP2022549172A (ja) 2022-11-24
CA3154756A1 (en) 2021-03-25
TWI889705B (zh) 2025-07-11
CN116942811A (zh) 2023-10-27
CN120289653A (zh) 2025-07-11
CN114641495A (zh) 2022-06-17

Similar Documents

Publication Publication Date Title
TWI889705B (zh) Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
US10869927B2 (en) Human endothelin receptor antibody and use thereof
KR102967396B1 (ko) Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
TWI842699B (zh) Gcgr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
EP4585617A1 (en) Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
CN114127126A (zh) ETA抗体与TGF-βTrap的融合蛋白质,以及其药物组合物和应用
HK40040729A (en) Gipr antibody and fusion protein of gipr antibody and glp-1, and pharmaceutical composition and application thereof
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
HK40015554A (en) Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
HK40016223B (en) Gcgr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
HK40016223A (en) Gcgr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
TW202304982A (zh) 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用
HK40020380A (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040729

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210319

Assignee: Zhengda Pharmaceutical (Guangzhou) Co.,Ltd.

Assignor: GMAX BIOPHARM LLC

Contract record no.: X2023990000864

Denomination of invention: GIPR antibody and its fusion protein with GLP-1, as well as its pharmaceutical composition and application

License type: Exclusive License

Record date: 20231016